CEO total compensation of $14.5 million is reasonable for the leader of a $35 billion market cap biotech company that achieved 877% stock price appreciation over 3 years — substantially outperforming the XBI — SPDR S&P Biotech ETF — and successfully launched a second commercial product in 2025. Approximately 94% of the CEO's pay is variable and at-risk, which is well above the policy's 50-60% minimum threshold, and the company uses meaningful performance conditions including relative total shareholder return modifiers on its performance stock awards. The prior year advisory vote received 97% support, the company maintains a robust compensation clawback policy, and no policy flags were triggered.

Non-audit fees of $7,725 are only 0.3% of audit fees of $2,487,516, well below the 50% threshold that would raise independence concerns. Ernst & Young is a Big 4 firm appropriate for a company of Insmed's size. Auditor tenure is not disclosed in the proxy, so no tenure trigger can fire — the absence of tenure disclosure is noted as a minor negative but does not warrant a negative vote under policy.